Could a new drug finally silence chronic cough?

NCT ID NCT04765722

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether mepolizumab, a drug already used for asthma, can reduce coughing in people with chronic cough and eosinophilic airway disease. 46 adults received either the drug or a placebo over 12 weeks. The main goal was to see if cough frequency decreased, measured by a special monitor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Mepolizumab (Nucala)

What this could lead to

If successful, this could point toward a new treatment option for chronic cough in people with certain airway conditions.

What could go wrong

This is a small, early proof-of-concept study with only 46 participants, so results may not apply to everyone. The drug may not significantly reduce cough frequency.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma Chronic Cough

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • McMaster University

    Hamilton, Ontario, L8S 4L8, Canada